The overlap between binge eating disorder and substance use disorders: Diagnosis and neurobiology
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
BACKGROUND AND AIMS: Binge eating disorder (BED) is a relatively common condition, especially in young adult females, and is characterized by chronic over-consumption of food resulting in embarrassment, distress, and potential health problems. It is formally included as a disorder in DSM-5 for the first time, an acknowledgement to its debilitating nature. This article explores the overlap between binge eating disorder and substance use disorders (SUD). METHODS: The bibliographic search was a computerized screen of PubMed databases from January 1990 to the present. Binge eating disorder, substance use disorder, binging, obesity, food addiction, comorbidity, dopamine, opioid, serotonin, glutamate, and pharmacological treatment were the keywords used in searching. RESULTS: BED shares similar phenomenology to SUD, including significant urges to engage in binging episodes, resulting in distress and impairment. Similar neurobiological pathways are found in both BED and SUD and medications based on similar neurobiology have been examined for both disorders. A subset of individuals with BED may have a "food addiction", but there is no clinical agreement on the meaning of "food addiction". Exploring the relationship between BED and obesity may also shed light on the extent to which BED can be viewed as an addiction. CONCLUSIONS: Overall, nascent research regarding BED and SUD suggests an overlap between these disorders, but there are discrepancies between these two disorders that need further exploration.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Drug Addiction, Dysregulation of Reward, and Allostasis
Koob, G. (2001) · Neuropsychopharmacology · doi:10.1016/s0893-133x(00)00195-0 · Cited by 2,953
Wang, G.-J., Volkow, N. D., Logan, J., Pappas, N. R., Wong, C. T., Zhu, W., Netusll, N., & Fowler, J. S. (2001) · The Lancet · doi:10.1016/s0140-6736(00)03643-6 · Cited by 1,864
A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation
Jorenby, D. E., Leischow, S. J., Nides, M. A., Rennard, S. I., Johnston, J. A., Hughes, A. R., Smith, S. S., Muramoto, M. L., Daughton, D. M., Doan, K., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199903043400903 · Cited by 1,585 · cited 1×
“Past research found bupropion, a selective reuptake inhibitor of dopamine and norepinephrine, effective for decreasing nicotine and food related cravings (Brody et al., 2004; Jain et al., 2002; Jorenby et al., 1999).”
BackgroundPreliminary validation of the Yale Food Addiction Scale
Gearhardt, A. N., Corbin, W. R., & Brownell, K. D. (2009) · Appetite · doi:10.1016/j.appet.2008.12.003 · Cited by 1,369
Avena, N. M., Rada, P., & Hoebel, B. G. (2008) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2007.04.019 · Cited by 1,358
Kessler, R. C., Berglund, P. A., Chiu, W. T., Deitz, A. C., Hudson, J. I., Shahly, V., Aguilar-Gaxiola, S., Alonso, J., Angermeyer, M. C., Benjet, C., et al. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.11.020 · Cited by 1,338
Introduction to Behavioral Addictions
Grant, J. E., Potenza, M. N., Weinstein, A., & Gorelick, D. A. (2010) · The American Journal of Drug and Alcohol Abuse · doi:10.3109/00952990.2010.491884 · Cited by 1,242
Self-citationObesity and addiction: Neurobiological overlaps
Volkow, N. D., Wang, G. ‐., Tomasi, D., & Baler, R. D. (2013) · Obesity Reviews · doi:10.1111/j.1467-789x.2012.01031.x · Cited by 800
Volkow, N. D., Wang, G.-J., Telang, F., Fowler, J. S., Thanos, P. K., Logan, J., Alexoff, D., Ding, Y.-S., Wong, C., Ma, Y., et al. (2008) · NeuroImage · doi:10.1016/j.neuroimage.2008.06.002 · Cited by 573
Wang, G.-J., Volkow, N. D., Thanos, P. K., & Fowler, J. S. (2004) · Journal of Addictive Diseases · doi:10.1300/j069v23n03_04 · Cited by 502
McElroy, S. L., Arnold, L. M., Shapira, N. A., Keck, P. E., Rosenthal, N. R., Karim, M. R., Kamin, M., & Hudson, J. I. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.2.255 · Cited by 484
Obesity and the brain: how convincing is the addiction model?
Ziauddeen, H., Farooqi, I. S., & Fletcher, P. C. (2012) · Nature Reviews Neuroscience · doi:10.1038/nrn3212 · Cited by 462
Pharmacological Treatment of Alcohol Dependence: A Review of the Evidence
Garbutt, J. C., West, S. L., Carey, T. S., Lohr, K. N., & Crews, F. T. (1999) · JAMA · doi:10.1001/jama.281.14.1318 · Cited by 444
Sugar and Fat Bingeing Have Notable Differences in Addictive-like Behavior
Avena, N. M., Rada, P., & Hoebel, B. G. (2009) · The Journal of Nutrition · doi:10.3945/jn.108.097584 · Cited by 388 · cited 2×
“The differential impact of fat binging could be a result of the activation of the inhibitory neuropeptide galanin-induced by fat binging, which may inhibit the opiate-like withdraw response (Avena et al., 2009).”
BackgroundBupropion SR Enhances Weight Loss: A 48‐Week Double‐Blind, Placebo‐ Controlled Trial
Anderson, J. W., Greenway, F. L., Fujioka, K., Gadde, K. M., McKenney, J., & O'Neil, P. M. (2002) · Obesity Research · doi:10.1038/oby.2002.86 · Cited by 315 · cited 2×
“…dosages of 300 mg/d and above) in placebo-controlled trials which involved overweight and obese subjects taking the bupropion, coupled with a 400 to 600 daily calorie deficit, reporting significant weight loss when compared to placebo (Anderson et al., 2002; Gadde et al., 2001; Jain et al., 2002).”
BackgroundDavis, C. A., Levitan, R. D., Reid, C., Carter, J. C., Kaplan, A. S., Patte, K. A., King, N., Curtis, C., & Kennedy, J. L. (2009) · Obesity · doi:10.1038/oby.2009.52 · Cited by 314
Enhanced Striatal Dopamine Release During Food Stimulation in Binge Eating Disorder
Wang, G., Geliebter, A., Volkow, N. D., Telang, F. W., Logan, J., Jayne, M. C., Galanti, K., Selig, P. A., Han, H., Zhu, W., et al. (2011) · Obesity · doi:10.1038/oby.2011.27 · Cited by 313
Bupropion SR vs. Placebo for Weight Loss in Obese Patients with Depressive Symptoms
Jain, A. K., Kaplan, R. A., Gadde, K. M., Wadden, T. A., Allison, D. B., Brewer, E. R., Leadbetter, R. A., Richard, N., Haight, B., Jamerson, B. D., et al. (2002) · Obesity Research · doi:10.1038/oby.2002.142 · Cited by 205
Drewnowski, A., Krahn, D., Demitrack, M., Nairn, K., & Gosnell, B. (1995) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/61.6.1206 · Cited by 197
Comparison of Combined Bupropion and Naltrexone Therapy for Obesity with Monotherapy and Placebo
Greenway, F. L., Dunayevich, E., Tollefson, G., Erickson, J., Guttadauria, M., Fujioka, K., Cowley, M. A., & for the NB-201 Study Group (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-1350 · Cited by 179 · cited 1×
“The combination of bupriopion and naltrexone has also been found to significantly decrease weight over a 48-week period in a sample of obese patients (Greenway et al., 2009).”
BackgroundEffects of intravenous glucose on dopaminergic function in the human brain in vivo
Haltia, L. T., Rinne, J. O., Merisaari, H., Maguire, R. P., Savontaus, E., Helin, S., Någren, K., & Kaasinen, V. (2007) · Synapse · doi:10.1002/syn.20418 · Cited by 148
Pharmacological management of binge eating disorder: current and emerging treatment options
McElroy, S., Guerdjikova, A. I., Mori, N., & O’Melia, A. (2012) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s25574 · Cited by 74 · cited 2×
“Acamprosate, which is a glutamate N-methyl-D-aspartate receptor antagonist, may reduce mGluR5 function, and is approved for alcohol dependence (Miller et al., 2011), has been found to decrease food craving and weight gain in individuals with alcoholism (McElroy et al., 2011, 2012).”
Background
Cited by
An overview of links between obesity and mental health
Avila, C., Holloway, A. C., Hahn, M. K., Morrison, K. M., Restivo, M., Anglin, R., & Taylor, V. H. (2015) · Current Obesity Reports · doi:10.1007/s13679-015-0164-9 · Cited by 366
Kim, H. S., & Hodgins, D. C. (2018) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2018.00406 · Cited by 143
What Is Food Noise? A Conceptual Model of Food Cue Reactivity
Hayashi, D., Edwards, C., Emond, J. A., Gilbert-Diamond, D., Butt, M., Rigby, A., & Masterson, T. D. (2023) · Nutrients · doi:10.3390/nu15224809 · Cited by 80
“…with rodent models, semaglutide reduced alcohol drinking, potentially by modulating GABA neurotransmission in the central amygdala and infralimbic cortex [17], suggesting that GLP-1RAs might also have an impact on addictive behaviors, which share many neural pathways with eating behaviors [18–20].”
BackgroundThe microbiota, the gut and the brain in eating and alcohol use disorders: A ‘Ménage à Trois’?
Temko, J. E., Bouhlal, S., Farokhnia, M., Lee, M. R., Cryan, J. F., & Leggio, L. (2017) · Alcohol and Alcoholism · doi:10.1093/alcalc/agx024 · Cited by 76
“Notably, eating disorders (EDs) and alcohol and substance use disorders share neurobiological mechanisms that regulate these pathological behaviors and both disorders involve altered reward processing and related neural circuitries (Goodman, 2008; Schreiber et al., 2013).”
BackgroundYohn, S. E., Galbraith, J., Calipari, E. S., & Conn, P. J. (2019) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00601 · Cited by 36
Metadata
- Authors
- Schreiber, L. R. N., Odlaug, B. L., & Grant, J. E.
- Venue
- Journal of Behavioral Addictions
- Publisher
- Akademiai Kiado Zrt.
- Published
- 2013-12
- Volume
- 2
- Issue
- 4
- Pages
- 191-198
- ISSN
- 2062-5871 (ISSN-L)
- 2063-5303
- OpenAlex
- W1981063034
- Cited by
- 112
- References
- 22
- FWCI
- 2.12
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.